YD Bio (NASDAQ:YDES) Stock Price Down 9.1% – Here’s Why

YD Bio Limited (NASDAQ:YDES) traded down 9.1% during mid-day trading on Monday . The company traded as low as $7.62 and last traded at $7.62. 8,043 shares were traded during mid-day trading, a decline of 81% from the average session volume of 41,891 shares. The stock had previously closed at $8.38.

Analysts Set New Price Targets

YDES has been the subject of a number of recent research reports. Wall Street Zen upgraded YD Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Weiss Ratings restated a “sell (d+)” rating on shares of YD Bio in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, YD Bio has a consensus rating of “Sell”.

YD Bio Stock Performance

The business has a 50 day moving average of $10.54.

Hedge Funds Weigh In On YD Bio

An institutional investor recently raised its position in YD Bio stock. Geode Capital Management LLC raised its stake in shares of YD Bio Limited (NASDAQ:YDES) by 10.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 58,363 shares of the biotechnology company’s stock after acquiring an additional 5,292 shares during the period. Geode Capital Management LLC owned approximately 0.08% of YD Bio worth $711,000 as of its most recent SEC filing.

About YD Bio

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.